Multinational phase 3 study of tebentafusp for metastatic uveal melanoma

The multinational phase 3 IMCgp100-202 trial evaluated tebentafusp, a bispecific protein targeting gp 100-positive cells, for metastatic uveal melanoma. Patients were randomized to weekly tebentafusp or to control, consisting of investigator’s choice of single-agent pembrolizumab, ipilimumab, or dacarbazine. Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (HR 0.51; p<0.001) and progression-free survival at 6 months was 31% versus 19% (HR 0.73; p=0.01). Adverse events infrequently (2% of patients) led to discontinuation of tebentafusp treatment (quick take video summary).